Comparative Pharmacology
Head-to-head clinical analysis: THIOTHIXENE versus TRIFLUOPERAZINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THIOTHIXENE versus TRIFLUOPERAZINE HYDROCHLORIDE.
THIOTHIXENE vs TRIFLUOPERAZINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiothixene is a typical antipsychotic that blocks postsynaptic dopamine D1 and D2 receptors in the brain. It also has alpha-adrenergic and histamine H1 blocking activity, with minimal anticholinergic effects.
Trifluoperazine is a typical antipsychotic of the phenothiazine class. It blocks postsynaptic dopamine D1 and D2 receptors in the mesolimbic system, reducing dopaminergic neurotransmission. It also has antiemetic effects via dopamine blockade in the chemoreceptor trigger zone and possesses anticholinergic, antihistaminergic, and alpha-adrenergic blocking properties.
Initial: 2 mg orally three times daily; maintenance: 5-30 mg/day orally in divided doses; maximum: 60 mg/day. IM: 4 mg 2-4 times daily; maximum 30 mg/day.
5-10 mg orally twice daily (maximum 40 mg/day), or 1-2 mg intramuscularly every 4-6 hours for acute symptoms (maximum 10 mg/day).
None Documented
None Documented
Clinical Note
moderateThiothixene + Deferasirox
"The serum concentration of Deferasirox can be increased when it is combined with Thiothixene."
Clinical Note
moderateThiothixene + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Thiothixene is combined with Fluticasone propionate."
Clinical Note
moderateThiothixene + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Thiothixene."
Clinical Note
moderateTerminal half-life: 10-20 hours (mean ~14 h). Clinical context: Steady-state achieved in ~2-3 days; allows once-daily dosing for maintenance.
Terminal elimination half-life: 12–24 hours; clinical context: requires 5–7 days to reach steady state; may be prolonged in elderly or hepatic impairment
Primarily renal: 65-70% as metabolites, <1% unchanged. Fecal: 15-20% via biliary elimination.
Primarily renal (approximately 70% as metabolites, <1% unchanged); fecal (approximately 30% via bile)
Category C
Category A/B
Typical Antipsychotic
Typical Antipsychotic
Thiothixene + Methylphenidate
"The risk or severity of adverse effects can be increased when Thiothixene is combined with Methylphenidate."